MedPath

SatRx LLC

SatRx LLC logo
🇷🇺Russia
Ownership
Private
Established
2010-01-01
Employees
251
Market Cap
-
Website
http://www.satrx.ru

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (100.0%)

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2017-03-23
Last Posted Date
2017-03-23
Lead Sponsor
SatRx LLC
Target Recruit Count
299
Registration Number
NCT03088670
Locations
🇷🇺

Non-state healthcare Organization "Road Clinical Hospital at the station Chelyabinsk Open Joint Stock Company" Russian Railways, Chelyabinsk, Russian Federation

🇷🇺

State Budget Healthcare Institution of Moscow "Endocrinology Dispensary", Moscow, Russian Federation

🇷🇺

SEI HPE "First Moscow State Medical University n.a. I.M. Sechenov of Ministry of Health and Social Development of the Russian Federation", Chair of faculty therapy #2 based at SHI of Moscow "City clinical hospital #61", Moscow, Russian Federation

and more 24 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.